PINCELL
6.5.2020 18:02:10 CEST | Business Wire | Press release
PinCell , a biotechnology company developing novel therapies for rare dermatological diseases, announced today the appointment of Gabriella Camboni, M.D., as Chief Executive Officer of PinCell and Member of the Board of Directors, and Luigi Costa as Chairman of the Board. Paola Pozzi, Partner at Sofinnova Partners, also joins PinCell’s Board following a successful seed financing of €1.65 million led by Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan. The financing was part of a series of investments recently made through The Sofinnova Telethon Fund , the largest fund in Italy dedicated to early-stage biotech startups targeting cures for rare and genetic diseases.
Dr. Camboni is a clinical pharmacologist with 18 years of experience in oncology drug development. She is Chief Executive Officer of BiovelocITA, Italy’s first biotech accelerator, co-founded by Sofinnova Partners in 2015. Dr. Camboni is also co-founder and Chief Operating Officer at Ethical Oncology Science (EOS), an Italian startup dedicated to translational medicine in oncology. Previously, Dr. Camboni co-founded and acted as Head of Development at Novuspharma, a biopharma developing innovative treatments for cancer. Both EOS and Novuspharma are part of Sofinnova Partners’ portfolio alumni.
“I am happy to have the opportunity to help develop a game-changing treatment together with an outstanding scientific team and my long-term associates of Sofinnova Partners,” commented Dr. Camboni.
PinCell also bolstered its Board of Directors with the appointment of Luigi Costa as Chairman of the Board. Mr. Costa has over 25 years of international pharmaceutical and biotech experience. He is an Entrepreneur in Residence at Sofinnova Partners and was the CEO of Nordic Nanovector, a biopharma developing novel targeted therapies for cancer. He also served as Board Member of Oncopeptides AS, a clinical stage biotech company developing a new treatment for Multiple Mieloma. Previously Mr. Costa was Regional Head International at Onyx Pharmaceuticals, acquired by Amgen in 2014, and held several leadership positions with Amgen including Head of International Oncology Franchise, General Manager of Italy and President of France, Amgen’s largest market outside the US. He also held various leadership positions of increasing responsibility with Eli Lilly both in Europe and in the US.
“I am very pleased to have the opportunity to support PinCell in the development of its innovative treatment for a severe autoimmune disease. I am confident that PinCell’s outstanding scientific team, together with my colleagues at Sofinnova Partners, will be able to bring a new therapeutic option to patients," said Mr. Costa.
PinCell’s lead program targets a rare autoimmune bullous disease called Pemphigus, which is characterized by blistering and erosions of the skin and mucous membranes. The condition is chronic, debilitating and potentially life-threatening. PinCell’s unique solution uses an innovative mechanism that inhibits the development of the typical skin blisters, without suppressing the immune system. This is a central factor that makes the treatment less prone to immune-related side effects, enabling patients to have a better quality of life.
Ms. Pozzi commented: “We are pleased to invest in this exceptional team of serial entrepreneurs who have significant clinical expertise in dermatological disorders. They have built strong relationships with US pharma-experienced consultants and international patients’ associations.”
The financing secured last month will advance the company’s development of first-in-class anti-inflammatory therapies for the treatment of rare and severe skin diseases with limited therapeutic options.
Carlo Pincelli, M.D., Professor of Dermatology at the University of Modena and Reggio Emilia and Co-founder of PinCell, said: “We are delighted to have secured financing from Sofinnova Partners, an investor with unparalleled authority and expertise in the biotech domain, as well as the support of experienced biotech executives. Together we are confident we will progress towards clinical studies for the benefit of patients suffering from these debilitating skin conditions.”
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe skin diseases with high unmet medical need. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Dr. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
For more information, please visit: www.pincell.it
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200506005517/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Parse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune Biology29.10.2026 13:00:00 CET | Press release
Licensable perturbation dataset to include transcriptomes and proteomic secretomes for understanding the human immune response Parse Biosciences, the leading provider of scalable and accessible single-cell sequencing and a QIAGEN company, and Nomic Bio, a leader in high throughput proteomic profiling, today announced their partnership to generate Cascade, a 100 Million cell foundational dataset to understand the human immune response. The dataset's scale and depth will give pharma partners cellular- and protein-level insight into immune biology, accelerating their ability to identify and validate new drug targets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029559438/en/ Cascade has already drawn foundational partner commitments from leading pharmaceutical and biotechnology companies, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, underscoring the demand for large-scale, multimodal immune data in drug
CSC Named Winner of the Top InfoSec Innovator Award for Most Innovative DNS Security29.10.2026 13:00:00 CET | Press release
CSC’s Subdomain Monitoring recognized for innovation in mitigating subdomain hijacking risks from dangling DNS CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and Domain Name System (DNS) threats, today announced that its Subdomain Monitoring solution took top honors for Most Innovative DNS Security in Cyber Defense Magazine’s 2026 Top InfoSec Innovator Awards. CSC introduced Subdomain Monitoring after analyzing close to half a million DNS records and finding that many companies were exposed to subdomain takeovers due to dangling DNS. CSC’s solution helps enterprises reduce this risk and secure their online ecosystems. It was the first and only technology on the market to ease the burden of tracking and maintaining DNS records and purging unused zone records to prevent subdomain hijacking. Subdomain Monitoring, powered by CSC’s one-of-a-kind DomainSecSM threat intelligence platform, alerts DNS administrators and security engineers when it
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 12:27:00 CET | Press release
EMA has validated two marketing authorization applications from Daiichi Sankyo in the EU for single-pill triple-combinations of established lipid-lowering agents: bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin If approved, the proposed therapies could be the first oral single-pill triple-combinations for lipid-lowering in the EU, aiming to simplify treatment for patients requiring multiple lipid-lowering agents The submissions reflect the commitment of Daiichi Sankyo to addressing unmet needs in cardiovascular disease The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinu
NIQ and Google Partner to Advance Agentic Commerce29.10.2026 11:45:00 CET | Press release
Built with Google Cloud and Gemini for business, NIQ and Google commit to transforming AI-driven product discovery, availability, and measurement Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable,
TradeStation Europe Expands Options Capability, Including Extended-Hours Trading29.10.2026 11:43:00 CET | Press release
Expanded intraday and options trading capability, combined with lower options and equities commissions across the Netherlands and the EEA TradeStation Europe B.V. (“TradeStation Europe”), the recently licensed European brokerage subsidiary of TradeStation Group, Inc. (“TradeStation”), today announced a round of product updates, including extended-hours options trading, along with reduced options and equities pricing, new single-stock option spreads and expanded intraday trading to enhance the offering for retail and institutional traders across the Netherlands and the European Economic Area (EEA). Extended-hours options trading is now live. Clients can trade eligible equity options during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and an extended curb session from 4:00 p.m. to 4:15 p.m. ET. The launch follows Cboe Global Markets, Inc.’s (Cboe: CBOE) introduction of extended trading hours for options on 24 individual stocks and five ETFs, expanding access to some of the most ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom